{"id":"W2898590494","doi":"10.1093/annonc/mdy287.079","title":"Pembrolizumab in patients with recurrent or metastatic cutaneous squamous cell carcinoma (cSCC): The phase II KEYNOTE-629 study","year":2018,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Nonmelanoma Skin Cancer Studies","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"ca_institutions":"Princess Margaret Cancer Centre","funders":"EMD Serono; Genentech; MorphoSys; Swedish Orphan Biovitrum; Astellas Pharma; Regeneron Pharmaceuticals; Eisai; GlaxoSmithKline; Merck; Symphogen; Bristol-Myers Squibb; AstraZeneca; Amgen; Pfizer","keywords":"Medicine; Pembrolizumab; Common Terminology Criteria for Adverse Events; Tolerability; Response Evaluation Criteria in Solid Tumors; Internal medicine; Oncology; Adverse effect; Clinical endpoint; Phases of clinical research; Head and neck squamous-cell carcinoma; Cancer; Surgery; Clinical trial; Head and neck cancer; Immunotherapy","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001849012,0.001397411,0.001572715,0.0002815902,0.0004695141,0.001060902,0.000789152,0.001485494,0.006026666],"category_scores_gemma":[0.0009541979,0.0005007125,0.00129154,0.0003546787,0.0004893304,0.000995817,0.0003713729,0.002993387,0.001528308],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.000763853,"about_ca_system_score_gemma":0.001307673,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0006922435,"about_ca_topic_score_gemma":0.001785649,"domain_scores_codex":[0.9996694,0.0001392131,0.0000208149,0.00006235263,0.00004190419,0.00006624717],"domain_scores_gemma":[0.9994884,0.00006927333,0.0001172908,0.00004482273,0.0000636757,0.0002166947],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","study_design_scores_codex":[0.6095272,0.07737286,0.008274846,0.005014353,0.003223943,0.0005981509,0.000382459,0.002811878,0.04409276,0.0008513439,0.02261979,0.2252305],"study_design_scores_gemma":[0.7840325,0.1911898,0.01157271,0.0002278673,0.0008008872,0.0004560422,0.00007726371,0.001153829,0.00174605,0.0003053736,0.008406432,0.00003115339],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9579246,0.0161067,0.001196155,0.002004127,0.0004393457,0.009274079,0.003921255,0.0002480954,0.008885715],"genre_scores_gemma":[0.9663017,0.00871262,0.00213486,0.004601632,0.0003642913,0.006684652,0.005063417,0.0000469758,0.00608999],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.006026666,"threshold_uncertainty_score":0.02016115,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.06840397306266671,"score_gpt":0.3853811545560575,"score_spread":0.3169771814933908,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}